Articles, Resources & Announcements
BioCentriq, a cell and gene therapy development and manufacturing center, is pleased to announce that Shannon Eaker of Cytiva has joined its advisory committee. Shannon earned his Ph.D. from the University of Tennessee, Knoxville in …
Read more
NEWARK, NJ, March 23, 2021 – BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, announces its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology …
Read more
Under this partnership, experts from BioCentriq and Tevogen Bio will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will utilize the processes and technology required to …
Read more
FOR IMMEDIATE RELEASE: Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA’s Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT …
Read more
If your start-up company has developed a biological product and is planning to file an investigational new drug (IND) application with the FDA or register the product with another federal agency, and you don’t have …
Read more
The New Jersey Innovation Institute (NJII) and Choose New Jersey will be hosting a virtual ribbon cutting, tour and panel discussions to mark the opening of BioCentriq™ on Thursday, October 29 at 2:30pm. RSVP to …
Read more
A research report published just yesterday by Allied Market research affirms that the global viral vectors and plasmid DNA manufacturing market generated $918.37 million in 2019, and is projected to reach $4.97 billion by 2027, …
Read more
The New Jersey Innovation Institute’s Biopharma Division, which includes BioCentriq, its cell and gene therapy development and manufacturing center, has welcomed Beth Thompson-Webb to its advisory committee. Thompson-Webb has more than two decades of experience in life sciences …
Read more
Dr. Haro Hartounian is senior vice president and general manager of the Biopharma Division of the New Jersey Innovation Institute (NJII). The division, founded in 2015, includes a state-of-the-art cell and gene therapy development center …
Read more
NJII announces that qualification and validation of its clinical manufacturing facility for cell and gene therapies is underway, and the name of the center will be BioCentriq. May 4, 2020: Newark, N.J. – Today the …
Read more